Biotech fundraising on public markets showed renewed momentum this week as Eikon Therapeutics priced a $381 million IPO and peers Agomab and SpyGlass raised a combined $350 million. The flurry of listings—part of a broader several‑company push—signals growing investor appetite for specialized drug developers, particularly those focused on oncology and novel modalities. Eikon will use proceeds to advance multiple clinical-stage programs, while Agomab and SpyGlass intend to fund pipeline development and commercial preparations. Analysts say the wave—if sustained—could re-open a reliable exit route for venture-backed biotechs and recalibrate valuations for clinical-stage assets.